[Fever and maculopapular exanthema as first manifestation of lymphoma].
Fernández Fernández
F J
FJ
Puerta Louro
R
R
González Vázquez
L
L
Soto Ríos
C
C
de la Fuente Aguado
J
J
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D005076:Exanthema / Q000175:diagnosis / Q000209:etiology*; D005334:Fever / Q000175:diagnosis / Q000209:etiology*; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D016393:Lymphoma, B-Cell / Q000150:complications / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy; D008297:Male; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D013902:Radiography, Thoracic; D000069283:Rituximab; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone